SLC5A2 and type 2 diabetes mellitus: The lean tissue mass that mainly includes the muscle mass showed no significant change following SGLT2 inhibitor treatment in one study [157], while in another study, the loss of muscle mass, alongside the loss of fat mass in patients with T2D, was observed in response to SGLT2 inhibition [82].